Welcome to our dedicated page for Xenon Pharmaceut SEC filings (Ticker: XENE), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
This page provides access to U.S. Securities and Exchange Commission filings for Xenon Pharmaceuticals Inc. (Nasdaq: XENE), a neuroscience-focused biopharmaceutical company developing azetukalner and other ion channel modulators for epilepsy, major depressive disorder (MDD), bipolar depression (BPD), and pain. As a foreign private issuer incorporated in Canada and listed on The Nasdaq Global Market, Xenon uses SEC reports to disclose financial results, executive changes, and other material events.
Among the key documents available here are Form 8-K filings, which Xenon uses to report quarterly financial results, business updates, and corporate developments such as the appointment of its Chief Financial Officer and related employment and equity arrangements. These filings often reference the company’s Phase 3 clinical programs in focal onset seizures (FOS), primary generalized tonic-clonic seizures (PGTCS), MDD, and BPD, as well as its early-stage NaV1.7, Kv7, and NaV1.1 programs.
Investors can also review exhibits attached to 8-Ks, including press releases that summarize results of operations and financial condition, R&D spending, and cash runway expectations, along with risk-focused forward-looking statements. Additional filings detail governance and compensation matters, such as severance protections and equity inducement grants made under Xenon’s inducement equity incentive plans.
On Stock Titan, these SEC filings are updated in near real time from EDGAR and are paired with AI-powered summaries that highlight key points, explain technical language, and help users quickly identify information about Xenon’s clinical pipeline, executive changes, and financial disclosures. Users can also locate information relevant to insider and equity-related activity through option and restricted share unit grant disclosures contained in the company’s current reports.
Xenon Pharmaceuticals appointed Thomas (Tucker) Kelly as Chief Financial Officer, effective October 15, 2025. He becomes the company’s principal financial and accounting officer, bringing prior CFO experience from Deciphera Pharmaceuticals and earlier leadership roles across life sciences finance and banking. Ian Mortimer will cease serving as interim CFO and continues as President and CEO.
Kelly’s employment terms include a $540,000 annual base salary, an annual incentive opportunity up to 45% of base salary, a one-time grant of 225,000 stock options, and 30,000 RSUs under the 2025 Inducement Plan. If terminated without cause outside a change of control period, severance equals 12 months of base salary plus one month per year of service (capped at 18 months), pro‑rated Average Bonus, retirement contributions for the severance period, and limited continued vesting and exercisability. During a change of control period, severance includes 100% target bonus, full vesting acceleration, and extended exercisability as outlined.
Xenon Pharmaceuticals insider transactions by Ian Mortimer show the reporting person exercised a fully vested option to buy 25,000 common shares at $7.69 and simultaneously sold 25,000 shares under a prearranged Rule 10b5-1 plan on 10/01/2025. The sale proceeds reflect an aggregate weighted-average price of $40.16 per share (individual sales ranged $40.00 to $40.495). After these transactions Mortimer directly beneficially owned 31,302 shares and indirectly owned 14,300 shares through his spouse, totaling 45,602 shares. The filing states the option exercised is fully vested and exercisable and that the sales were executed under a 10b5-1 plan.
Xenon Pharmaceuticals (XENE) filed a Form 144 reporting a proposed sale of 25,000 common shares through Canaccord Genuity Corp. on the NASDAQ with an aggregate market value of $1,004,117. The filer states the shares were acquired and paid for on 10/01/2025 by exercising options issued by the company and paid in cash. The notice lists 77,105,799 shares outstanding and reports no securities sold by the filer in the past three months. Some standard filer identification fields (CIK/Contact) are blank in the provided text.
Xenon Pharmaceuticals Inc. (XENE) filed a Form 144 notice reporting a proposed sale of 2,548 common shares through Morgan Stanley Wealth Management Canada Inc. on the NASDAQ with an aggregate market value of $94,490. The shares were acquired on 09/19/2025 by exercise of options from the issuer and were paid via a net exercise on the same date. The filing shows 77,105,799 shares outstanding and reports no securities sold in the past three months by the selling person. The notice includes the standard representation that the seller is not aware of undisclosed material adverse information about the issuer.
Xenon Pharmaceuticals (XENE) received a Schedule 13G/A disclosing that Wellington-affiliated filers report beneficial ownership of 2,174,761 common shares, representing 2.83% of the class. The filing shows no sole voting or dispositive power and shared voting power of 2,146,462, with shared dispositive power of 2,174,761, indicating the positions are managed jointly by Wellington entities.
The filing states these securities are owned of record by Wellington clients and held in the ordinary course of business, not for the purpose of changing or influencing control of the issuer. No client is identified as owning more than 5% of the class.
Xenon Pharmaceuticals Inc. reported results for the quarter ended June 30, 2025. Management states it held $624.8 million of cash, cash equivalents and marketable securities and expects these resources to fund operations for at least the next 12 months. Total assets were $674.3 million and total liabilities were $40.3 million, leaving shareholders' equity of $634.0 million. The company recorded a net loss of $149.8 million for the six months ended June 30, 2025 (net loss of $84.7 million for the three months), and an accumulated deficit of $1,049.2 million.
Research and development spending rose to $136.2 million for the six months, driven by azetukalner program costs (direct costs of $74.9 million). Collaboration revenue of $7.5 million was recognized related to a Neurocrine milestone; NBI-921355 is in Phase 1. Clinically, X-TOLE2 patient recruitment is complete with topline data anticipated in early 2026, and multiple Phase 3 trials (X-TOLE3, X-ACKT, X-NOVA2/3, X-CEED) are underway or enrolling.
Xenon Pharmaceuticals Inc. announced via press release dated August 11, 2025 that it is furnishing its financial results for the three and six months ended June 30, 2025. The press release is attached as Exhibit 99.1 and, per the filing, the information is furnished to the SEC rather than filed.
The company reiterates that it distributes material information through SEC filings, press releases, conference calls, its corporate and investor websites, and social media channels. The filing identifies the company trading as XENE on the Nasdaq Global Market and is signed by Ian Mortimer, Chief Executive Officer and Interim Chief Financial Officer.
Filing: Schedule 13G/A by FMR LLC and Abigail P. Johnson reporting beneficial ownership in XENON PHARMACEUTICALS INC (CUSIP 98420N105). The statement reflects an event date of 06/30/2025 and signature dated 08/05/2025.
Holdings: Aggregate beneficial ownership is 8,824,363 shares, representing 11.5% of the class. On the cover data FMR LLC reports sole voting power of 8,824,348, sole dispositive power of 8,824,363, and zero shared voting/dispositive power. Abigail P. Johnson is reported with sole dispositive power of 8,824,363 and no voting power shown. The filing states the securities were acquired and are held in the ordinary course of business and not to change or influence control of the issuer. Exhibit 99 and Exhibit 24 (power of attorney) are referenced.
FAQ
What is the current stock price of Xenon Pharmaceut (XENE)?
What is the market cap of Xenon Pharmaceut (XENE)?
